Is there another chapter in the Helicobacter pylori/peptic ulcer disease story?
The role of Helicobacter pylori in the production of mucosal damage has largely been considered within a simple infection paradigm, because to date eradication has appeared to be a predictable outcome of antibiotic therapy. Changes in the epidemiology and management of peptic ulcer disease, however, require a more comprehensive framework to understand these shifting clinical patterns. The present review examines mucosal damage as an outcome of a complicated host-parasite relationship, with alterations in both parasite physiology and host defence mechanisms being keys to understanding disease patterns.
Clancy
R L
RL
Discipline of Immunology and Microbiology, University of Newcastle and Vasse Research Institute, New South Wales, Australia. rclancy@mail.newcastle.edu.au
Pang
G
G
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D005753:Gastric Mucosa / Q000382:microbiology; D016481:Helicobacter Infections / Q000382:microbiology*; D016480:Helicobacter pylori / Q000187:drug effects / Q000302:isolation & purification; D006801:Humans; D010437:Peptic Ulcer / Q000188:drug therapy / Q000382:microbiology*
D000900:Anti-Bacterial Agents